PH
PHARM
PHARM
No data for this timeframe.
Vol
SEC Reports2
Press Releases7
Recent Activity
Jun 4, 2026
announcement
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming today announced that the U.S. FDA accepted its sNDA resubmission for Joenja® (leniolisib) t
May 28, 2026
Press
Pharming Group announced that shareholders approved all proposals at its 2026 Annual General Meeting, including the appo
Impact 2/10
May 7, 2026
Press
Pharming announced multiple presentations at the 2026 CIS Annual Meeting, including interim data from a long-term extens
Impact 3/10
May 7, 2026
SEC
Pharming Group reported Q1 2026 total revenues of $72.4M, an 8% decline YoY, driven by a 15% drop in RUCONEST® revenue (
PRESS-RELEASE — Impact 6/10
Apr 2, 2026
SEC
Pharming Group N.V. announced the filing of its 2025 Annual Report and Form 20-F with the SEC, providing a comprehensive
PRESS-RELEASE — Impact 3/10
Latest Reports
NEUTRAL
Press
2/10
Pharming Group announced that shareholders approved all proposals at its 2026 Annual General Meeting, including the appo
May 28, 2026
MIXED
PRESS-RELEASE
6/10
Pharming Group reported Q1 2026 total revenues of $72.4M, an 8% decline YoY, driven by a 15% drop in RUCONEST® revenue (
May 7, 2026
NEUTRAL
PRESS-RELEASE
3/10
Pharming Group N.V. announced the filing of its 2025 Annual Report and Form 20-F with the SEC, providing a comprehensive
Apr 2, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 4.5/10.
NEUTRAL
2/10
Pharming Group announced that shareholders approved all proposals at its 2026 Annual General Meeting
May 28, 2026
NEUTRAL
3/10
Pharming announced multiple presentations at the 2026 CIS Annual Meeting, including interim data fro
May 7, 2026
NEUTRAL
3/10
Pharming Group N.V. announced it will report preliminary unaudited financial results for Q1 2026 on
Apr 23, 2026
NEUTRAL
3/10
Pharming Group announced that its CEO and Chief Medical Officer will present at two upcoming investo
Apr 7, 2026
BULLISH
8/10
Pharming Group N.V. announced a positive opinion from the EMA's CHMP recommending marketing authoriz
Mar 27, 2026
BULLISH
8/10
Pharming Group announced that Japan's Ministry of Health, Labour and Welfare has approved Joenja® (l
Mar 24, 2026
MIXED
7/10
Pharming Group reported strong full-year 2025 results with 27% revenue growth to $376.1 million, dri
Mar 12, 2026
No analyst rating data available yet. Consensus ratings and individual firm actions are collected periodically from financial data providers.
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
announcement
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming today announced that the U.S. FDA accepted its sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Jun 2, 2026
other
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York. Thursday June 4, 2026 at 11:05 EDT/17:05 C
May 28, 2026
announcement
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
Pharming Group announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held on May 28, 2026.
May 22, 2026
other
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union
Pharming announces the European Commission (EC) has granted Marketing Authorization for Joenja (leniolisib)
May 7, 2026
announcement
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
Pharming today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS) in New Orleans, LA.
May 7, 2026
earnings
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2
Apr 23, 2026
announcement
Pharming Group to report first quarter 2026 financial results and provide business update on May 7
Pharming to report first quarter 2026 financial results & provide a business update on May 7, 2026 & host conference call 13:30 CEST/07:30 EDT.
Apr 16, 2026
other
Pharming Group announces the 2026 Annual General Meeting of Shareholders
Pharming Group N.V. 2026 Annual General Meeting to be be held on Thursday May 28, 2026, at 14:00 CET. Meeting documents available on website Pharming.
Apr 7, 2026
announcement
Pharming Group to participate in April investor conferences
Pharming announced that management will participate in investor conferences Needham Virtual Healthcare and Kempen Life Sciences Conferences in April 2
Apr 2, 2026
earnings
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
Pharming Group today announced filing of its 2025 Annual Report and Annual Report on Form 20-F, available at annualreport.pharming.com.
Mar 27, 2026
announcement
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
Pharming announces positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
Mar 24, 2026
announcement
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
<p align="justify"><b>Leiden, the Netherlands, March 24, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq
Mar 12, 2026
earnings
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow